

REMARKS/ARGUMENTS

Favorable reconsideration of this application is requested in view of the amendments above and the remarks which follow.

DISPOSITION OF CLAIMS

Claims 53, 55, 58-75 are pending in this application. Claim 53 has amended as set forth above to create a patentably distinct composition. Claim 53 recites a liquid antiviral drug composition consisting of an antiviral drug solubilized in a polysorbate surfactant. Claim 75 is new and recites that the liquid antiviral drug composition of claim 53 is contained within a sustained release dosage form. The remaining claims have been amended as set forth above to be consistent with claims 53 and 75.

REJECTIONS UNDER 35 U.S.C. §103

Claims 53, 55, and 58-74 were rejected as being obvious over Rudnic et al. (U.S. Patent No. 5,952,004) in view of Eckenhoff et al. (U.S. Patent No. 4,692,326) and further in view of Al-Razzak et al. (U.S. Patent No. 5,559,158). Reconsideration of the rejection of claims 53, 55, and 58-74 is respectfully requested.

Rudnic *et al.* do not teach a liquid antiviral drug composition consisting of an antiviral drug solubilized in a polysorbate surfactant, as recited in amended claim 53. Eckenhoff *et al.* and Al-Razzak et al. also fail to overcome the deficiency in Rudnic *et al.* Therefore, claim 53 is not obvious over Rudnic *et al.* in view of Eckenhoff *et al.* and further in view of Al-Razzak et al. It is noted that Al-Razzak et al. teach a solid pharmaceutical composition comprising an adsorbent to which is adsorbed a mixture of an organic solvent, an HIV protease inhibitor, an acceptable acid and optionally oils, surfactants, and antioxidants. Al-Razzak et al. do not teach an antiviral drug solubilized in a liquid polysorbate surfactant alone. Withdrawal of the rejection of claim 53 over Rudnic *et al.* in view of Eckenhoff *et al.* and further in view of Al-Razzak et al. is respectfully requested. Claims 55, 58-63, 73, and 74, being dependent on claim 53, are also patentable in view of the foregoing arguments.

Claim 64 ultimately depends from claim 53 and recites the structure of the sustained release dosage form in which the liquid antiviral drug composition of claim 53 is contained.

Claim 64 is also not obvious over Rudnic *et al.* in view of Eckenhoff *et al.* and further in view of Al-Razzak *et al.* in view of the foregoing arguments with respect to claim 53. Withdrawal of the rejection of claim 64 is respectfully requested. Claims 65-72, being dependent on claim 64, are also patentable in view of the foregoing arguments.

CONCLUSION

Applicant believes that this paper is fully responsive to the Office Action dated July 27, 2006, and respectfully requests that a timely Notice of Allowance be issued in this case. The undersigned would welcome the opportunity to discuss the application with the Examiner if such a discussion would facilitate allowance of the application.

Please apply any charges not covered or credits in connection with this filing to Deposit Account No. 50-3202 (ref. ARC2644R1).

Date: November 27, 2006

Respectfully submitted,
DEWIPAT Incorporated

By Adenike Adebisi
Adenike A. Adebisi
Reg. No. 42,254
Tel.: (281) 856-8646